Scientific research in Brazil shows that the Brazilian P1 variant of the coronavirus is causing a fatal increase in covida-19 cases in this Latin American country, and its mutation will make it easier to avoid antibodies.
The Fiocruz Institute of Public Health conducted a study of a mutation spread in Brazil and found that the virus spike area used to enter and infect human cells had mutations.
Brazilian scientists have warned that these mutations may make the virus more resistant to targeted spiked vaccines, which would have potentially serious consequences for the spread of the disease in the most populous country in Latin America.
Felipe Naveca, one of the authors of this study from Fiocruz, said: “We think this is another hidden mechanism of virus production that can avoid antibody reactions.”
Naveka said the change appears to be similar to the mutation seen in the more aggressive South African variant, and as some studies have shown, certain vaccines have greatly reduced their effectiveness against this mutation.
He added: “This is particularly worrying because the virus continues to accelerate its evolution.”
Studies have shown that variant P1 is 2.5 times more infectious than the original coronavirus and has higher resistance to antibodies.
On Tuesday, as Latin America’s largest economy became increasingly isolated, France suspended all flights to and from Brazil to prevent the spread of this variant.
This variant quickly became dominant in Brazil and is considered to be the main factor in the second wave of the epidemic. The death toll in this country exceeds 350,000, making it the second-largest death toll in the world after the United States.
The epidemic in Brazil is also increasingly affecting young people. Hospital data shows that in March, more than half of all intensive care patients were under the age of 40.
For Ester Sabino, a scientist at the University of São Paulo School of Medicine, who led Brazil’s first coronavirus genome sequencing, the mutation of the P1 variant is not surprising given the rapid spread of the virus.
She said: “As in Brazil, if the level of transmission is high, the risk of new mutations and mutations will increase,” she said.
So far, vaccines (such as those developed by AstraZeneca and China Sinovac) have been shown to be effective against Brazilian variants, but Sabino said that further mutations may make it was in danger.
She said: “It is indeed possible.”